Collagen clue reveals new drug target for untreatable form of lung cancer


Collagen, the stuff of ligaments and skin, and the most abundant protein in the human body, has an extraordinary role in triggering chemical signals that help protect the body from cancer, a new study has revealed.

Novel chemotherapies are used more often on-label than off-label

Novel chemotherapies are used more often on-label than off-label

In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

Metformin shows benefit in ovarian cancer


Use of the oral antidiabetes drug metformin improved survival in women with ovarian cancer, according to the findings of a retrospective case-control study.

Regorafenib prolongs survival in face of GI cancers

Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.

Suppressed protein halted melanoma metastasis

Inhibiting one protein eliminated metastasis of melanoma in lab studies, a finding that could lead to targeted therapies for a range of cancers.

Blood test paired with gene sequencing to detect cancer


The ability to detect cancer DNA in the blood has been combined with genome sequencing technology in a test that could be used to screen for cancers, monitor cancer patients for recurrence, and find residual cancer left after surgery.

Study shows cause of and potential cure for aggressive leukemia

Excessive levels of interleukin-15 initiate large granular lymphocyte (LGL) leukemia, but also represent a promising therapeutic target.

Everolimus shrinks astrocytoma brain tumors

The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.

Withdrawn leukemia drug has good results in UK study

Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.

Drug combo shows promise in triple-negative breast cancer

Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.

All PARP inhibitors not created equal in terms of PARP-trapping power

Research findings indicate that PARP inhibitors vary from one another in their ability to trap PARP proteins.

Repeat glioblastoma surgeries may prolong life

Persons with glioblastoma who undergo repeated resections can have improved survival, indicate the findings of a recent study.

Noninvasive technique predicts patients' response to chemotherapy


Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.

Noninvasive technique predicts patients' response to chemotherapy


Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.

Triple-drug regimen controls brain metastasis in breast cancer

Combining trastuzumab and lapatinib with an anti-VEGFR2 antibody dramatically improved survival in HER2 breast cancer with brain metastases.

New targeted therapy for prostate cancer has anti-tumor activity in phase I trial


Levels of circulating tumor cells and of prostate specific antigen were reduced by a new drug in patients who had already failed previous chemotherapy and hormone treatments.

Expectations too high for palliative chemotherapy

Many persons who receive chemotherapy for incurable cancers may not understand that the treatment is unlikely to be curative.

Gene patterns guide prognosis in castration-resistant prostate cancer

Two separate research teams identified genes that can predict outcomes in men with castration-resistant prostate cancer (CRPC).

Radiotherapy after prostatectomy has long-term benefits

Administering radiotherapy after prostatectomy helped nearly two-thirds of users in a recent study remain free of prostate cancer after 10 years.

Advanced melanoma controlled with chemotherapy/ immunotherapy combo

A combination of chemotherapy and immunotherapy appears to be a labor-intensive but feasible treatment for persons with metastatic melanoma.

IUD aids treatment of endometrial cancer

An intrauterine device releasing the progestin levonorgestrel was effective therapy for early endometrial cancer in women not fit for surgery.

Vaccine for existing HPV infection may thwart cervical cancer

A therapeutic vaccine for women who are already harboring human papillomavirus (HPV) appeared to fight cervical cancer in a small, phase 1 study.

Newfound PARP-1 role becomes a promising target in prostate cancer


Scientists discovered PARP-1 contributes to the growth and progression of androgen receptor-positive prostate cancer cells.

HIV drug effective against HER2 breast cancer

Nelfinavir, a protease inhibitor used in the treatment of HIV, has been found to inhibit the growth of HER2-positive tumors in mice.

Taxanes do more than stop prostate tumor cell division

New insights into the action of taxanes on androgen receptors in prostate cancer shed light on why a patient may not respond to these drugs.

HF/CM risks in breast chemotherapy

HF/CM risks in breast chemotherapy

Earlier study findings that anthracycline- or trastuzumab-based treatment for breast cancer raises the risk for heart failure and cardiomyopathy can be extended to a more general population of women.

Aspirin helps in some cancers

Aspirin helps in some cancers

Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.

FDA Update - September/October 2012

News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).

Dual drug therapy delayed treatment resistance in melanoma

Two drugs under FDA evaluation slowed treatment resistance in persons with metastatic malignant melanoma positive for the BRAF protein.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs